Table 3 Pharmacodynamic model estimates of the final model for [¹⁷⁷Lu]Lu-PSMA-I&T

Structural parameters

Baseline PSA (µg/L)

140^a

 Tumor volume on baseline PSA (µg/L)^b

57.5 (38.9%)

15.5–101.6

PSA growth rate (k_G) (h⁻¹)

0.000408 (14.2%)

0.000286–0.000517

Direct drug-induced effect (k_{D, direct}) (L·day⁻¹·GBq⁻¹)

0.00335 (40.1%)

0.000961–0.006147

Rate constant effect compartment (k_e0) (h⁻¹)

0.00128 (13.1%)

0.00105–0.00171

Delayed drug-induced effect (k_{D, delay}) (L·day⁻¹·MBq⁻¹)

0.0000328 (17.4%)

0.0000235–0.0000450

Box-cox shape parameter

 −0.822 (28.3%)

 −1.24 to −0.414

Inter-individual variability

Baseline PSA (CV%)

179 (17.4%)

151–210

k_G (CV%)

90.9 (32.6%)

64.2–121

k_{D, direct} (CV%)

140 (51.2%)

61.0–206

k_{D, delay} (CV%)

87.5 (26.1%)

66.1–109

Residual unexplained variability

Proportional error (CV%)

29.3 (9.2%)

27.0–32.2